Collagen is a high molecular weight fibrous protein which is exceptionally heterogeneous, and at least six distinct types are currently recognized. These proteins contain 11 or more individual chains (Bornstein & Sage 1980) which are genetically and structurally different. If gene duplication is similar to that for the haemoglobin genes (Weatherall 1979) , then the capacity for genetic variation must be considerable. In the past 10 years there have been a number of important advances in the biochemistry of collagen (Table 1) which has established its diversity and led to an understanding of a number of rare genetic diseases (Pinnel et al. 1972 , Lichtenstein et al. 1974 , Pope et al. 1977 , DiFerrante et al. 1975 , Siegel et al. 1979 . These diseases are tabulated in Tables 2 & 4 and include 8 types of Ehlers-Danlos syndrome (EDS), with at least six defects, four or more types of osteogenesis imperfecta with 10 or more biochemical abnormalities (Byers et al. 1981 , and three varieties of the Marfan syndrome with 2 or more collagen mutations (Byers et al. 1981b ).
The knowledge gained in the understanding of the molecular basis for these rare abnormalities has also been useful in comprehending the causes of more common diseases. A good example is inherited type III collagen deficiency which occurs as a homozygous disease in lethal arterial EDS IV (Pope et al. 1977) , but which is also closely associated in a less severe form with congenital aneurysms of the circle of Willis. This latter disease is sufficiently common to cause an estimated 4000 deaths per year in the United Kingdom ). Furthermore, the recent rapid advances in DNA technology and genetic engineering methods (Emery 1981) complement protein chemical analysis with gene characterization so that faulty genes and proteins can both be identified in particular human diseases. Thus the recognition of relatively simple gene defects such as partial or complete collagen chain deletions is already a reality, and intrauterine diagnosis from amniocentesis is possible in at least some of them. In addition, interesting recent advances in the electron microscopy of collagen fibril morphology now allows the sophisticated study of collagen fibril patterns (Vogel et al. 1979 , Fj0lstad & Helle 1974 .
In some instances clinical disease can be understood in terms of a genetic (DNA) defect producing a faulty protein chain, the assembly and packing of which becomes sufficiently distorted to produce a whole spectrum of disease symptoms and signs such as increased cutaneous extensibility, hypermobile joints, easy bruising, brittle bones and fragile arteries, etc. In this paper we will describe how abnormalities of type I and type III collagens can produce a variety of human disorders including various types of Ehlers-Danlos syndrome, osteogenesis imperfecta and congenital berry aneurysms of the cerebral circulation.
Osteogenesis imperfecta (01) (Tables 2 & 3) This is an inherited osteoporosis in which brittle, easily-fractured, collagen-depleted bones are accompanied by a variety of connective tissue abnormalities including blue sclerae, thin fragile skin, hyperextensible joints, hernias, mitral valve prolapse, and increased arterial fragility. Striking abnormalities of collagen biochemistry are increasingly common in this disease, which is clinically and genetically heterogeneous. The bones are markedly collagen (Figure 1 ) and often have a distorted architecture. Clinically, the disease ranges from a relatively mild almost trivial disorder (Figure 2 ), compatible with a normal life span, through all degrees of severity (e.g. Figure 3 ), to a lethal severely distorting short-limbed dwarfism, fatal either in utero or very shortly after birth (Figure 4 ).
The clinical severity of the disease can, to some extent, be correlated with the genetics, and (Table 2) . When the known biochemical abnormalities are correlated with Sillence's classification, a comprehensive analysis of the disease becomes possible (Table 3) . Since bone collagen is almost entirely type I (al(I)2a2), nearly all the known abnormalities affect either the al or the a2 chain of this molecule. The types of protein chain abnormalities so far identified are reminiscent of the haemoglobinopathies with probable aminoacid substitutions , Nicholls et al. 1983 ), short peptide deletions (Barsh & Byers 1981) , abnormally migrating protein chains (Nicholls et al. 1983 , Byers et al. 1981a , Barsh et al. 1982 , and complete deletions of particular protein chains (Nicholls et al. 1979 ). It is not entirely clear why similar though widely disparate diseases such as mild OI type I (Turakainen et al. 1980 ) and severe OI type II can show similar biochemical changes, i.e. greatly diminished type I relative to type III collagen in culture. One possible explanation is the deletion of a single or duplicated gene in both instances, with the retention of a normal allele in the mild disease and a diseased one in the severe. That is, the mild disease is heterozygous and the severe doubly heterozygous for an 01 collagen mutation. Better protein analytical techniques together with DNA restriction enzyme analysis, Southern blotting and gene hybridization should resolve this question in the near future. As an illustration of how protein and DNA analysis can be exploited to unravel the molecular pathology of OI, we describe below some recent biochemical data on a child with moderately severe 01 type III where the a2 chain of type I collagen is completely deficient.
Case report A 6-week-old boy from North Germany presented with multiple spontaneous fractures of arm and leg bones. He was examined at 21 months when the clinical features included blue sclerae, a persistent anterior fontanelle, soft thin easily bruised skin with unusually visible veins, normal teeth, multiple healed fractures with callus formation and a relatively normal architecture ( Figure 5 ). His clinically normal parents were third cousins. Skin fibroblast cultures were established and tissue collagens were examined by get electrophoresis and column chromatography using standard techniques. In some instances whole collagen chains were cyanogen bromide cleaved for peptide analysis.
The propositus showed no collagen type I Ot chains either in tissue culture or whole skin when tested by a variety of techniques. Furthermore, his clinically normal parents were heterozygous in this respect and made only 50% of the expected levels of these proteins. Differential salt precipitation experiments then showed that skin (and by implication bone) type I collagens from this patient contained al trimer (al(I)3) i-nstead of the usual al(I)2a2 hybrids. The mechanism by which a2 chain deficiency causes brittle bones is unclear but this disease demonstrates two important points. First, although a2(I) chains have been heavily conserved in evolution and occur in species as diverse as dogs and dogfish, they are not A Figure compared with his parents and a normal control. Type I collagen has been separated into its acl and a2 chains on tube gels which have then mm into gel been sliced and scintillation counted essential for life. Secondly, they confer upon bone its normal properties of rigidity, flexibility and strength, for in their absence bones are brittle. Yet the deficiency is not life threatening, as other tissues such as skin, tendons and blood vessels seem perfectly normal and heterozygotes with only half the normal levels are completely healthy in every way ( Figure  6 ).
The absent a2 chains immediately suggested the possibility that the gene for a2(I) was deleted in this patient. Other possibilities include faulty transcription of gene to messenger RNA (mRNA) or an error within the mRNA sequence such as a premature stop codon, or a deletion, substitution or other mutation of such a nature as to prevent incorporation of the mutated protein chain into the collagen type I triple helix. We have investigated these possibilities in collaboration with Susan Deak, Jeanne Myers and Darwin Prockop of the Rutgers University Medical School and David Rowe of the University of Connecticut using recombinant DNA technology with a probe to human collagen a2(I) cDNA. So far we have established by Southern blotting that the gene for human a2(I) is present, and by Northern blotting that the two normal-sized mRNA species are transcribed. Additionally, cell free translation in a reticulocyte-lysate system shows a collagenous product which comigrates with authentic procollagen a2 chains. Nevertheless the normal a2 chain product cannot be detected in medium from cultured skin fibroblasts.
It is unclear whether the cell free translated chain is actually pro x2 collagen or whether it is an al(I) derivative which happens to comigrate in this position. If the former applies then presumably the translated a2 chain is very rapidly degraded so that it is undetectable in fibroblast culture and is incapable of incorporation into the normal al(I)a2 triple helix. If the latter is true (i.e. no pro a2 chains are produced in cell free translation) then in the presence of a normal gene and normal-sized message, a premature stop codon or a mutation which completely alters the properties of the translated protein would be possible.
Whatever the final explanation, this disease can be rapidly diagnosed by fetoscopic skin biopsy and analysis for collagen a2 chains. It should only be a matter of time before the precise genetic abnormality is identified and the possibility of amniotic cell analysis becomes a reality. There is, of course, a close resemblance to the molecular abnormalities which cause the various haemoglobinopathies.
Ehlers-Danlos syndrome (EDS) ( Table 4 ) This is a group of inherited defects of connective tissue sharing certain physical features such as hypermobile joints; silky, soft, stretchy fragile skin which often heals with characteristically thin paper tissue scars; bruising, hernias, blue sclerae and various minor deformities such as pectus excavatum and congenital dislocation of the hips. Some types show particular predispositions to short stature, scoliosis and skeletal abnormalities, arterial rupture and a severe premature peridontal disease, respectively, which the others lack. This allows them to be categorized into special and mutually-exclusive groups (Table 4 ). The clinical type can be partially correlated with the genetic pattern and the biochemical abnormality (Table 4 ). The disorder is heterogeneous and each subgroup contains several closely related subtypes. Thus EDS VI in which lysine residues are not hydroxylated because of lysyl hydroxylase inactivity or deficiency (and which was the first of these diseases to have a biochemical abnormality recognized) now has at least three subgroups. Similarly EDS IV has four or more varieties of type III collagen deficiency. Until very recently EDS type I and II which have the most obvious and least ambiguous clinical signs had no recognizable biochemical abnormality identified. Although alterations and irregularities of collagen fibril diameter, examined in transverse section in the transmission electron microscope, have been described (Holbrook & Byers 1978 , Patterson & Munrow 1977 , implying some abnormality of microfibrillar packing and perhaps assembly. We have been especially interested in EDS IV in which the clinical combination of prematurely aged hands, feet and face has led to the term acrogeria (meaning prematurely aged extremities). Here thin skin and arterial fragility correlates with the spectrum of type III deficiency ranging from zero to 15% of normal. This is accompanied by. clinically and histologically thin, collagen depleted skin (Table V) .
Clinical features
Type III collagen predominates in skin, arteries, intestines and pleuroperitoneal (mesothelial) linings. The main clinical features of the disease reflect these facts with thin, prematurely aged skin producing a typically owl-eyed, hollow-cheeked, peaky-nosed, thinlipped facial appearance which is reminiscent of partial lipodystrophy (Figure 7 ). There is usually thin, prematurely aged skin over the extremities and a prominent venous pattern is especially characteristic although not invariable. The skin texture and appearance is reminiscent of generalized steroid atrophy, which differs in showing a reduction in all Figure 7 . Face and hands ofpatient affected with collagen type III deficient EDS IV. Prominent eyes, thin lips and pinched nose are typical of the disease. The prematurely aged hands are those of a 29-year-old woman and give rise to the term 'acrogeria' meaning prematurely aged extremities collagens rather than a type-specific deficiency, as in EDS IV. The appearance of the upper dermal collagen fibrils as viewed in transverse section with the transmission electron microscope is also interesting. Although overall the EDS IV group shows no alteration in mean fibril diameter at a variety of dermal depths from normal individuals, different patients show definite fibril pattern distortions. These include abnormally large fibrils, abnormally small ones and double populations of small and normal fibrils in different clinical types (Figure 8 ).
Arterial and generalized vascular fragility are the most important and life threatening abnormalities facing these patients. The fragility ranges from merely a prominent venous capillary pattern accompanied by easy bruising, to the sudden and catastrophic lethal rupture of large or medium-sized arteries such as the aorta (root or arch), pulmonary, carotid, axillary, renal, splenic, iliac, femoral and popliteal vessels. Even when surgical help is immediately available, the ligature or anastomosis of such fragile material is difficult and occasionally unsuccessful (McKusick 1972) . At post-mortem the affected arteries are often unusually thin with a texture resembling soggy blotting paper. Such changes can be correlated in vivo with altered arterial compliance (Child et al. 1981) which is readily measured with a Doppler-Shift continuous wave ultrasound method. Patients with all varieties of type III collagen deficiency have abnormally extensible aortic walls. Thus in some unspecified fashion the presence of type III collagen allows normal arterial walls to withstand a lifetime of continuous distension and relaxation. In its absence the mechanical properties become altered in such a way as to induce premature splitting and fragility perhaps in a manner akin to certain types of metal fatigue.
Biochemical abnormalities
Type III collagen, measured by pepsin solubilized whole collagen chains or cyanogenbromide cleaved collagen peptides (Pope et al. 1975 , Pope et al. 1980 , is virtually absent from tissues such as skin, arteries, intestines and pleura of affected individuals. Furthermore, no type III procollagen or collagen is secreted into the medium of cultured skin fibroblasts from affected patients. Although in our experience the cell layer does not usually contain type III collagen, and others have failed to detect it using antibodies to type III collagen and procollagen (Gay 1976) , there is evidence that some types of EDS IV may be caused by a failure to secrete the protein which is subsequently retained with the cell layer (Byers et al. . In the majority of our patients, however, this is not the case. We have also studied an affected patient who makes a mutant type III collagen (unpublished).
A partial or complete failure to synthesize type III collagen is likely to be caused by errors in the genes coding for this protein; very much like the haemoglobinopathies (Weatherall 1979) . Possible errors include partial or complete gene deletion, intron-splicing abnormalities and various errors in the transcription from gene to messenger RNA. Alternatively, mutations of the message sequence might cause premature termination of the shortened type III chains which could not be successfully incorporated into a collagen triple helix and therefore subsequently degraded. An abnormality of collagen secretion with intracellular retention would be explained by a mutation of the procollagen extension peptides which bind the unexported protein to the membrane of the endoplasmic reticulum. Such abnormalities have already been identified in a form of lethal type II osteogenesis imperfecta (Barsh & Byers 1981) . Although these possibilities are at present speculative, when probes to genomic or cDNA human type III collagen genes become available it will be possible to test these hypotheses, as has already become possible for the a (Orkin et al. 1979) and ,B thalassaemias (Maniatis et al. 1975) , sickle cell disease (Kan & Dozy 1978) and some type I collagen defects (Prockop et al. 1979, Pope et al. in preparation) .
Ehlers-Danlos syndrome type II Ehlers-Danlos syndrome type I and II are both autosomal dominant diseases characterized by hypermobile joints, soft silky easily-split skin and a tissue-paper scarring over pressure areas such as the knees and elbows. Type II EDS has rather less obvious clinical signs than type I, but bruising is common. Although the clinical signs are much more striking than in other EDS variants and the texture and appearance of the skin are quite different from normal, until very recently no convincing biochemical abnormality has been found. Nevertheless minor abnormalities of collagen fibrillar diameter imply a collagen defect which may be subtle enough to be undetected by conventional protein chemical techniques. Accordingly, we have used a genomic probe to a human collagen ac(I) like gene (Weiss et 1982) to screen chromosomal DNA from a series of patients with EDS I and II for gene deletions. In an affected father and son with otherwise typical EDS II we have detected a 0.3 Kb deletion at the 3' end of this gene as evidenced by Barn and Eco RI restriction enzyme digestion patterns visualized by Southern blotting and autoradiography (Figure 9 ). Both digestions showed a new band, absent in controls, as well as the normal gene product which strongly suggests that both patients were heterozygous for a partial structural deletion for the type I-like gene. Furthermore, the patients were clinically abnormal and the inherited pattern clearly autosomal dominant. In addition their collagen fibril diameters were slightly distorted and disordered compared with normal ( Figure 10 ). Although we had previously screened the proteins produced in culture, when these were re-examined in the light of the genetic data, an abnormal collagen chain was detectable running lighter than al(I) on polyacrylamide gel electrophoresis (PAGE). At first glance this observation is entirely consistent with the notion of a small gene deletion at the 3' end of the gene and therefore at the C terminal end of the protein, but unfortunately the gene deleti'on localizes entirely in the procollagen extension. The apparently lighter helical collagen protein might therefore be either an anomaly or an entirely different collagen protein chain perhaps induced by an altered type I collagen gene. Although the two affected patients are heterozygous for the mutated and a normal structural gene, the traces of abnormal protein seem capable of interfering with collagen fibril assembly and packing as evidenced by the distorted electron microscopic pattern. The 14 other patients with EDS I or II that we have so far examined do not show this particular deletion but undoubtedly they do have abnormalities of their collagen chains which will be identified in due course. The information already available to us from this family suggests that intrauterine diagnosis by amniotic cell analysis is feasible, and would allow accurate genetic counselling. This will also become available for other similar variants in the foreseeable future.
More common collagen chain defects The rare genetic defects discussed in this paper can now be understood in a very sophisticated way in terms of their collagen genes and proteins. Although these diseases are rare and relatively unimportant, research which furthers our understanding of them also results in a better comprehension of more common diseases. A good example is the occurrence of type III collagen deficiency ( Figure 11 ) in a high proportion of patients with congenital berry aneurysms of the circle of Willis . Such aneurysms cause 4000 deaths per year in the United Kingdom and are a common cause of strokes in the young and middle aged. Aneurysms are commonest in the anterior and middle cerebral branches of 'the anastomosis, most frequently at branching points where the internal elastic lamina is discontinuous (Glynn 1940) and the arterial wall presumably weaker (Figure 12 ). Furthermore, the circle lies relatively unsupported in the subarachnoid space surrounded only by cerebrospinal fluid and much less well protected by most other arteries. Perhaps the specialized anatomy of the cerebral circulation predisposes it to varying degrees of minor vascular damage. In individuals with an inherent deficiency of arterial walls this could lead to aneurysm formation at the sites of natural weakness, i.e. branching points. Once the aneurysm starts, then hydrodynamic fluid mechanics allows a vicious spiral of rising pressure with increasing diameter which becomes self-perpetuating. Type III collagen deficiency is known to be associated with aortic aneurysms in the rare genetic disorders, and we therefore thought it reasonable to study its production in proven cerebral aneurysm patients. More than 2/3 of the 20 or more patients so far examined show a deficiency of this protein. More detailed studies will be required to unravel the genetics of the disease. As the measurement of type III collagen levels in cultured fibroblasts is so time consuming, we have elected (in collaboration with Dr Anne Child and Mr Glenn Neil-Dwyer) to screen cerebral aneurysm patients for defects of aortic distensibility with the Doppler Ultrasound probe. If type III deficient patients are always ultrasound abnormal, then this fast and reliable method can be used as the screening method and the type III levels checked in selected individuals.
Distensible arterial walls are likely to be caused by factors other than type III collagen including other collagens, elastin, mucopolysaccharide and muscle proteins. Furthermore, these possibilities do not exclude the influence of other aggravating factors such as hypertension, atheroma, cigarette smoking and various viral infections on the aetiology of this disease (Jones 1981) . Other common diseases in which collagen changes occur include senile osteoporosis, Achilles tendon rupture and osteoarthritis, all of which could be transmitted as single gene defects. When DNA probes to other collagen types such as types II, III and V collagen become available it will be possible to examine these possibilities in detail. More complicated problems in which fibrous tissue proliferates include normal wound repair, keloid scar formation, cirrhosis of the liver, the pulmonary fibroses and the various sclerodermas, which may also yield to the approaches outlined above provided that quick and reliable methods can be found for measuring collagen synthesis and degradation. Accurate measurement of messenger RNA with cDNA probes may go some way to solving the synthetic side of this equation. If these processes can be understood in terms of gene switching and regulation it is quite feasible that future pharmacological products will evolve with the capability of controlling and even reversing them in selected cases.
